MedTrace Logo

Reversal of Botulinum Neurotoxin Injection Related Dysphonia With Pyridostigmine

NCT05110417 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-07-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects of pyridostigmine (Mestinon) on patient vocal outcomes after undergoing laryngeal botulinum neurotoxin (BoNT) injections, which is a standard treatment for spasmodic dysphonia. Pyridostigmine (Mestinon) has been used for treatment of BoNT overdose, and it is our hope that it will be beneficial in the management of post BoNT breathy phase.

Conditions

  • Dysphonia, Spastic
  • Dysphonia
  • Laryngeal Dystonia

Interventions

DRUG

Pyridostigmine Bromide 60 Milligrams (mg)

One tablet will be provided to patients during the second visit.

Sponsors & Collaborators

  • Eastern Virginia Medical School

    lead OTHER

Principal Investigators

  • Benjamin Rubinstein, MD · Eastern Virginia Medical School Department of Otolaryngology - Head and Neck Surgery

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-20
Primary Completion
2022-12-31
Completion
2023-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05110417 on ClinicalTrials.gov